Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Mol Cancer Ther. 2014 Nov 19;14(1):183–192. doi: 10.1158/1535-7163.MCT-14-0584

Figure 6.

Figure 6

SRT1720 reduces tumor xenograft growth in a SIRT1-dependent and -independent manner. A, SRT1720 increases autophagy and ER stress markers in neu-expressing mouse cancer cells after 8 hours of treatment. B, Percentage of viable neu cells after treatment of SRT1720 and NH4Cl. Co-treatment with NH4Cl significantly reduced the death of neu cells treated with SRT1720 (P < 0.001, ***). C, Immunoblot showing knockdown of SIRT1 in neu cells. D, Graph showing neu tumor volume of control (n=10) and SIRT1 (n=10) knockdown tumors in mice treated with SRT1720. There was a 69% decrease in tumor volume of sh-control tumors (P < 0.001, ***) after SRT1720 treatment as compared to a 23% decrease in sh-SIRT1 tumors (P < 0.05, *) after SRT1720 treatment. E, Graph of neu tumor mass from control (n=10) and SIRT1 (n=10) knockdown tumors after SRT1720 treatment. There was a significant decrease in tumor mass in sh-control tumors (P < 0.0001, ***) but not in sh-SIRT1 tumors (P = 0.0545)